Neurocrine Biosciences Inc., a San Diego company developing drugs for neurological and endocrine disorders, is banking $250 million in a public offering of about 6.9 million shares priced at $36 each to fund a growing roster of trials, rising R&D costs and plans to market its phase III tardive dyskinesia therapy, NBI-98854, ahead of an anticipated 2016 filing of its new drug application (NDA) for the movement disorder.